Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.48 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.47 |
| ▸ | CPA1 | P15085 | 2/20 | 0.46 |
| ▸ | CPB1 | P15086 | 1/20 | 0.46 |
| ▸ | CPA3 | P15088 | 1/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 3/20 | 0.45 |
| ▸ | MMP3 | P08254 | 3/20 | 0.45 |
| ▸ | MMP9 | P14780 | 3/20 | 0.45 |
| ▸ | MMP13 | P45452 | 2/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 7/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9558884 | 0.85 | PLA2G2A (0.49) | ANPEPPLA2G10CPA3BACE1PLA2G2A | |
| SCHEMBL9558971 | 0.85 | ANPEP (0.46) | ANPEPPLA2G10MMP2MMP3MMP9 | |
| SCHEMBL5275561 | 0.81 | GABBR2 (0.49) | ANPEPPLA2G10BACE1CYP3A4CYP2C9 | |
| SCHEMBL11863917 | 0.78 | KIF11 (0.58) | ANPEPBACE1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL11863901 | 0.78 | KIF11 (0.58) | ANPEPBACE1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL9558477 | 0.77 | PLA2G2A (0.45) | ANPEPPLA2G10BACE1CYP3A4CYP2C9 | |
| SCHEMBL9850035 | 0.75 | CAPN1 (0.44) | ANPEPPLA2G10BACE1CYP3A4CYP2C9 | |
| SCHEMBL1420805 | 0.75 | ANPEP (0.67) | ANPEP | |
| SCHEMBL7089333 | 0.75 | CPA1 (0.67) | CPA1CPB1CPA3CPB2 | |
| SCHEMBL7386200 | 0.75 | CPA1 (0.67) | CPA1CPB1CPA3CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1856074-A2 | SUBSTITUTED ARYL OR HETEROARYLSULFONYLBUTANAMIDES FOR USE AS ANTI-INFLAMMATORY AGENTS | Amgen, Inc (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20060111347-A1 | Substituted sulfones and methods of use | AMGEN INC. (US) | 2006-05-25 | — | — | US | disclosed |
| WO-2006041888-A2 | SUBSTITUTED ARYL OR HETEROARYLSULFONYLBUTANAMIDES FOR USE AS ANTI-INFLAMMATORY AGENTS | AMGEN INC. (US) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111347-A1 | Substituted sulfones and methods of use | SULT2A1, STS, SULT1A1 | ANPEP 1930/4885PLA2G10 2239/4885CPA1 2284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.